E-LIB Suche - Ergebnisse für: Carpeño, J.d.C.

1

EP04.01-002 Costs of Locoregional and Metastatic Recurrence..:

Carpeño, J.d.C. ; Insa, A. ; Collado, R....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S246 , 2022

Link: https://doi.org/10.1016/..

2

EP11.03-05 Molecular Characterization and Prognosis of Pati..:

Gutiérrez Sainz, L. ; Villamayor, J. ; Higuera, O....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S620-S621 , 2023

Link: https://doi.org/10.1016/..

3

187P Tissue B-cell receptor repertoire as biomarker of comp..:

Sierra-Rodero, B. ; Martínez-Toledo, C. ; Molina-Alejandre, M....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S141-S142 , 2023

Link: https://doi.org/10.1016/..

4

EP16.01-007 Molecular Characterization by Next-Generation S..:

Castellanos, P. Cruz ; Alonso, R. Rosas ; Ozaez, I....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S558 , 2022

Link: https://doi.org/10.1016/..

5

EP08.02-088 Mutational Status of KRAS, STK11 and CDKN2A Gen..:

Cruz Castellanos, P. ; Rosas Alonso, R. ; Ozaez, I....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S443-S444 , 2022

Link: https://doi.org/10.1016/..

6

EP08.01-048 Spanish Immunotherapy Registry of Cardiovascula..:

Gutiérrez Sainz, L. ; Cruz Castellanos, P. ; Higuera Gómez, O....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S361-S362 , 2022

Link: https://doi.org/10.1016/..

7

2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in ..:

Gettinger, S. ; Schenker, M. ; De Langen, J....
Immuno-Oncology and Technology. 16 (2022) - p. 100107 , 2022

Link: https://doi.org/10.1016/..

8

OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk..:

Casarrubios, M. ; Cruz-Bermúdez, A. ; Sierra-Rodero, B....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S6-S7 , 2022

Link: https://doi.org/10.1016/..

9

EP16.02-014 A Comparative Analysis of Gene Alteration Detec..:

Ozaez, I. ; Hernández, I. ; Cruz-Castellanos, P....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S577 , 2022

Link: https://doi.org/10.1016/..

10

Five-year outcomes from the randomized, phase 3 trials Chec..:

Lind, M. ; Gettinger, S. ; Borghaei, H....
Lung Cancer. 139 (2020) - p. S49-S50 , 2020

Link: https://doi.org/10.1016/..

11

PACIFIC: Overall Survival with Durvalumab versus Placebo af..:

Raben, D. ; Faivre-Finn, C. ; Spigel, D....
International Journal of Radiation Oncology*Biology*Physics. 102 (2018) 5 - p. 1607-1608 , 2018

Link: https://doi.org/10.1016/..

12

NSCLC Patients With Brain Metastases Treated With Platinum-..:

Smit, E. ; Moro-Sibilot, D. ; de Castro Carpeño, J....
International Journal of Radiation Oncology*Biology*Physics. 90 (2014) 5 - p. S47 , 2014

Link: https://doi.org/10.1016/..

13

PCN126 OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURV..:

Heron, L. ; De Castro Carpeño, J. ; Chouaid, C....
Value in Health. 14 (2011) 3 - p. A177-A178 , 2011

Link: https://doi.org/10.1016/..

14

Prognostic value of carcinoembryonic antigen level in recta..:

Moreno García, V. ; Cejas, P. ; Blanco Codesido, M....
International Journal of Colorectal Disease. 24 (2009) 7 - p. 741-748 , 2009

Link: https://doi.org/10.1007/..

15

9164 An indirect comparison of the efficacy of bevacizumab ..:

Walzer, S. ; de Castro Carpeno, J. ; Vergnenegre, A.V....
European Journal of Cancer Supplements. 7 (2009) 2 - p. 555 , 2009

Link: https://doi.org/10.1016/..